Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In the search for new medicines for cancer or inflammatory disorders, small molecules are invaluable tools for testing the activity of possible target proteins. Those small chemical compounds can also affect the morphology and phenotype of cell samples collected from patients, opening the possibility to develop new therapeutics.

Q: What is your approach to helping develop new drugs?

Kilian Huber: If you want to develop a new drug, it is important that you have a good target whose activity you would want to modulate with that drug. Then of course the question is how do you come up with a good target and that is what our lab is mainly interested in. We try to develop new approaches that can help to identify new targets that are relevant for the treatment of human disease.

Q: How do you go about identifying a new drug target?

KH: We are pursuing two different strategies. In one of them, we try to develop small molecule tools: small chemical compounds that people can use to test the activity of a given protein which is most likely to be the kind of target you are looking for within a cellular system or a tissue.

In the other approach, we take patient samples or human tissue and we incubate these samples with small molecules. Then we see how the small molecules affect the morphology and the phenotype of these cells. In, most cases we will not know how these compounds work, which is why we then take them and try to understand the mode of action, using a technology that we call chemical proteomics.

Q: Are there particular diseases that you are interested in?

KH: We are very much interested in human cancers and we study a broad variety of leukaemias and solid tumours. We are also interested in inflammatory disorders such as rheumatoid arthritis and viral infections.

Q: What are the most important lines of research that have emerged in the last 5-10 years?

KH: I think nowadays people appreciate much more the complexity of human biology and thus of human disease. People understand that it is very unlikely that you will be able to make a drug that interacts only with one protein and then will cure a disease. Diseases are very complex: often it is not just one protein that is acting weirdly within the cell, it will be several of them and if you alter the activity of one of them, the other will then compensate for it. It is important to use good model systems that are representative of the disease and we try to identify the molecules that are hitting all the right nodes in that network.

Q: Why does your line of research matter and why should be fund it?

KH: Our aim is to accelerate drug discovery by providing new targets to the community. We offer our reagents and tool compounds for free: everything is open access and anyone who wants to use it can get it for free from us. We do this to enable other researchers to further investigate these new targets, and also pharmaceutical companies, so that they can start drug discovery programmes. I think considering the burden of disease like cancer and inflammatory disorders, people will appreciate that it is important to have new therapeutics to be able to treat these disorders.

Q: How does your research fit into translational medicine within the department?

KH: For us it is very important that our results are relevant for the treatment of human disease. We want to see if our molecules really work in patient tissue. We collaborate with clinicians and we ask them to provide us with samples from patients. We then treat the samples with small molecules and then see if they give an interesting phenotype. Then we give these molecules back to the clinicians so they can then study the effects in patients.

Kilian Huber

Chemical Biology

The development of new medicines is dependent on the identification of novel drug targets. Chemical Biology combines chemistry and biology to generate small molecule called chemical probes, used to study the role of proteins as potential targets. Dr Kilian Huber uses different approaches to develop chemical probes that may provide leads for drug discovery.

More podcasts related to Translational & Clinical

David Stuart: Structural biology and vaccines

The basis of an effective vaccine is that a pathogen is physically recognised by the immune system.

Kay Grunewald: Structural cell biology of virus infection

Understanding the entirety of a virus’ ‘life cycle’ requires an understanding of its transient structures at the molecular level. Using imaging techniques allows us to understand the communication between the virus and the components of the cell it is infecting, which can ultimately help to treat infectious diseases.

Jens Rittscher: Biological imaging

Video microscopy aims to improve target discovery and drug development and to do so generates large volumes of data. Fluorescence labelling helps make intrinsic cellular functions visible and computational tools then enable analysis of these data sets to improve our understanding of cellular functions.

Sebastian Nijman: Pharmacogenomics

In the context of cancer, genetic diversity means that we respond differently to various treatments. Pharmacogenomics sits at the intersection between genetics and drugs. Better understanding of the genetic landscape of cancer and the recent increase of targeted drugs allow us to better match patients with the best treatments, improving care.

Ian Pavord: Asthma

Ian Pavord's research in to airway inflammation has resulted in mepolizumab being identified as an effective inhibitor of eosinophilic inflammation and asthma attacks. Mepolizumab is currently in Phase III clinical trials and if found to be effective could be a promising treatment for certain asthma patients.

Trudie Lang: The Global Health Network

The Global Health Network is a successful and growing online science park comprised of varied research communities for different health research groups and cross-cutting health topics. It is built for the research and wider health community by researchers and public health practitioners themselves. It is a trusted source of quality information, education and research tools.

Najib Rahman: Respiratory Medicine

Respiratory medicine encompasses a large number of common diseases like pneumonia, asthma, emphysema and lung cancer. Outcomes are currently relatively poor and the area of research is underfunded. Recent progress have been made towards personalising treatment, and Dr Rahman's research aims at improving patient care.

Chris O’Callaghan: Atherosclerosis & immunity

Atherosclerosis is the most important cause of death worldwide. It is caused by the accumulation of both fatty material and immune cells. Over time, these set up an inflammatory reaction which causes a lot of damage to the blood vessel wall. Although we do have good therapies designed to lower the levels of fatty material, we haven’t any therapies specifically designed to target the effect of the immune system. Professor O'Callaghan's group is working towards developing such therapies.

Stefan Knapp: Development of chemical probes

While drugs were initially developped by testing natural products directly in humans, the current approach is to use chemical probes. These are small chemical coumpounds that inhibit selected targets, avoiding side effects. Professor Knapp produces structures of molecular targets and makes them widely available. This will allow a faster and more cost effective development of new drugs.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.